Peptides News and Research

RSS

Scientists decipher new molecular signaling path that prompts protein degradation in muscle

Patients in advanced states of myocardial insufficiency generally lose their muscle mass and muscle strength. Indeed a fact that until now has negatively impacted the clinical course of the disease and that has resulted in poor prognoses for patients. Such pathological muscle loss impacts the skeletal muscles in particular.

11 Aug 2015

LA BioMed's Nagendra Mishra to be honored with 2015 ICAAC Young Investigator Award

Nagendra Mishra, PhD, a Los Angeles Biomedical Research Institute researcher will be honored by the American Society of Microbiology with a 2015 Interscience Conference of Antimicrobial Agents and Chemotherapy Young Investigator Award during the conference Sept. 17-21 in San Diego.

11 Aug 2015

Low GLSRV heralds adverse outcomes in PAH patients

Impaired global longitudinal strain of the right ventricle predicts adverse outcomes in patients with pulmonary arterial hypertension, say investigators.

10 Aug 2015

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced an Exclusive Channel Collaboration (ECC) to pursue the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder.

10 Aug 2015

Study may lead to effective antimicrobial treatment strategies for people with uncontrolled diabetes

Case Western Reserve scientists may have uncovered a molecular mechanism that sets into motion dangerous infection in the feet and hands often occurring with uncontrolled diabetes. It appears that high blood sugar unleashes destructive molecules that interfere with the body's natural infection-control defenses.

7 Aug 2015

Researchers show how microbiota protects against type 1 diabetes development

Our bodies have ten times the amount of microbes than human cells. This set of bacteria is called microbiota. In some instances, bacteria known as pathogens can cause infectious diseases. However, these micro-organisms can also protect us from certain diseases. Researchers from Inserm, Paris Descartes University and the CNRS (French National Centre for Scientific Research), through collaboration with teams from China and Sweden, have recently shown how microbiota protects against the development of type 1 diabetes.

7 Aug 2015

Scientists successfully test new tumor diagnosis method

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf, in cooperation with colleagues at the University of Zurich and the Ruhr-Universität Bochum, have for the first time successfully tested a new tumor diagnosis method under near-real conditions. The new method first sends out an antibody as a "spy" to detect the diseased cells and then binds to them.

4 Aug 2015

Atomic level images reveal how neuropeptide hormone neurotensin may activate its receptors

Many hormones and neurotransmitters work by binding to receptors on a cell's exterior surface. This activates receptors causing them to twist, turn and spark chemical reactions inside cells.

3 Aug 2015

Natural protein fragment produced in the brain can inhibit enzyme implicated in Alzheimer's disease

For the first time, UCLA researchers have shown that a natural protein fragment produced in the brain can act as an inhibitor of a key enzyme implicated in the onset of Alzheimer's disease, a finding that could lead to the development of new drugs to treat the disease.

30 Jul 2015

Moerae announces initiation of second MMI-0100 Phase 1 clinical trial for pulmonary disorders

Moerae Matrix Inc. announced today the initiation of its second Phase 1 clinical trial with MMI-0100, a first-in-class inhibitor of MAPKAP kinase 2 (MK2) that is being developed for pulmonary disorders characterized by inflammation and fibrosis. The study, conducted in the United Kingdom, is a double-blind, two-way cross-over design lipopolysaccharide (LPS) challenge study further evaluating the safety and tolerability of MMI-0100 when given via inhalation to healthy subjects who smoke.

29 Jul 2015

New study estimates link between coffee consumption habits and incidence of mild cognitive impairment

A new study by researchers at the University of Bari Aldo Moro, Bari, Italy, Geriatric Unit & Laboratory of Gerontology and Geriatrics, IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Foggia, Italy, and Istituto Superiore di Sanità, Roma, Italy, estimates the association between change or constant habits in coffee consumption and the incidence of mild cognitive impairment (MCI), evaluating 1,445 individuals recruited from 5,632 subjects, aged 65-84 year old, from the Italian Longitudinal Study on Aging (ILSA), a population-based sample from eight Italian municipalities with a 3.5-year median follow-up.

29 Jul 2015

Brazilian cardiovascular researcher receives Georg Forster Research Award

The cardiovascular researcher Professor Robson Augusto Souza dos Santos of the Federal University of Minas Gerais in Belo Horizonte, Brazil, has been awarded the Georg Forster Research Award of the Alexander von Humboldt Foundation.

28 Jul 2015

GLP-2 therapy may help fight neonatal parenteral nutrition-associated liver disease

A new study finds that exogenous glucagon-like peptide 2 (GLP-2) treatment may help fight neonatal parenteral nutrition-associated liver disease (PNALD).

28 Jul 2015

New Histone Antibody Specificity Database allows scientists to find right antibodies for biomedical research

For years, a crisis has been brewing in molecular biology. The problem is that antibodies--research tools used to identify key proteins at work in a cell--aren't always what they seem. Unreliable antibodies have led to numerous instances of false findings, failed experiments, and wasted money and samples.

24 Jul 2015

Study points to potential treatment for thrombotic thrombocytopenic purpura

A rare autoimmune disease creates sudden pain in the abdomen or the head, sending a patient to the emergency room with a potentially fatal condition. The pain comes from a multitude of blockages of tiny blood vessels, formed after the patient's own immune system somehow inhibits an enzyme that is vital to control clotting.

23 Jul 2015

New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).

22 Jul 2015

Study identifies new culprit in Alzheimer's disease development

A recent study conducted at Nathan S. Kline Institute for Psychiatric Research and NYU Langone Medical Center implicates a new culprit in Alzheimer's disease development. The research reveals that ßCTF -- the precursor of the amyloid beta (Aß) peptide -- acts at the earliest stage of Alzheimer's to initiate a range of abnormalities leading to the loss of groups of neurons critical for memory formation.

22 Jul 2015

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that data from its Phase I/II study of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published in Nature Medicine.

22 Jul 2015

Study reveals potential new therapeutic target for depression treatment

Increasing the levels of a signaling molecule found in the brain can positively alter response to stress, revealing a potential new therapeutic target for treatment of depression, UT Southwestern Medical Center researchers said.

22 Jul 2015

Alefacept drug offers clinical benefit to certain individuals with new-onset type 1 diabetes

Individuals with new-onset type 1 diabetes who took two courses of alefacept (Amevive®, Astellas Pharma Inc.) soon after diagnosis show preserved beta cell function after two years compared to those who received a placebo.

21 Jul 2015

Peptides News and Research

Scientists decipher new molecular signaling path that prompts protein degradation in muscle

LA BioMed's Nagendra Mishra to be honored with 2015 ICAAC Young Investigator Award

Low GLSRV heralds adverse outcomes in PAH patients

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Study may lead to effective antimicrobial treatment strategies for people with uncontrolled diabetes

Researchers show how microbiota protects against type 1 diabetes development

Scientists successfully test new tumor diagnosis method

Atomic level images reveal how neuropeptide hormone neurotensin may activate its receptors

Natural protein fragment produced in the brain can inhibit enzyme implicated in Alzheimer's disease

Moerae announces initiation of second MMI-0100 Phase 1 clinical trial for pulmonary disorders

New study estimates link between coffee consumption habits and incidence of mild cognitive impairment

Brazilian cardiovascular researcher receives Georg Forster Research Award

GLP-2 therapy may help fight neonatal parenteral nutrition-associated liver disease

New Histone Antibody Specificity Database allows scientists to find right antibodies for biomedical research

Study points to potential treatment for thrombotic thrombocytopenic purpura

New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

Study identifies new culprit in Alzheimer's disease development

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Study reveals potential new therapeutic target for depression treatment

Alefacept drug offers clinical benefit to certain individuals with new-onset type 1 diabetes

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News